Friday 11 August 2017

2017 - Record Breaking Year for Orphan Drug Approvals

Food and Drug Administration (FDA) is on track to set a record for orphan drugs approved this year. At last count, 42 orphan drugs have been approved between January 1, 2017 and August 9, 2017.

An orphan drug designation gives companies numerous tax breaks and filing fee exemptions during the review process. In addition, if a drug gets approved, the company receives 7 years of market exclusivity for that drug. With the addition of the pediatric rare disease priority review voucher, it is likely that even more companies will understand the financial and altruistic rewards that come from helping those in the rare disease community.


Below is a list of orphan drugs approved this year (till August 11 2017)


Generic Name Orphan Designation Designation Date Marketing Approval Date Exclusivity End
5-aminolevulinic acid Visualization of malignant tissue during surgery for malignant glioma (WHO grades III and IV) 1/15/2013 6/6/2017 6/6/2024
avelumab (Recombinant human monoclonal IgG1 antibody against programmed death ligand-1) Treatment of merkel cell carcinoma. 9/21/2015 3/23/2017 3/23/2024
brigatinib Treatment of anaplastic lymphoma kinase-positive (ALK+), c-ros 1 oncogene positive (ROS1+), or epidermal growth factor receptor positive (EGFR+) non-small cell lung cancer (NSCLC). 4/28/2016 4/28/2017 4/28/2024
C1-esterase-inhibitor, human, pasteurized Prevention and/or treatment of acute attacks of hereditary angioedema. 10/16/1992 6/22/2017 6/22/2024
ceritinib Treatment of patients with non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase(ALK)-positive 9/27/2013 5/26/2017 5/26/2024
cerliponase alfa Treatment of neuronal ceroid lipofuscinosis type 2 4/1/2013 4/27/2017 4/27/2024
Cytarabine:daunorubicin liposome injection Treatment of acute myeloid leukemia 8/22/2008 8/3/2017 TBD
d6-tetrabenazine, deutetrabenazine Treatment of Huntington's Disease 11/5/2014 4/3/2017 4/3/2024
dabrafenib and trametinib Treatment of patients with BRAF mutation positive non-small cell lung cancer. 10/29/2015 6/22/2017 6/22/2024
daratumumab Treatment of multiple myeloma 5/6/2013 6/16/2017 TBD
Deferasirox Treatment of chronic iron overload in patients with transfusion-dependent anemias 11/21/2002 5/18/2017 TBD
deferasirox Treatment of chronic iron overload in alpha-thalassemia 2/24/2015 5/18/2017 TBD
deflazacort Treatment of Duchenne muscular dystrophy 8/16/2013 2/9/2017 2/9/2024
edaravone Treatment of amyotrophic lateral sclerosis 5/12/2015 5/5/2017 5/5/2024
enasidenib Treatment of acute myelogenous leukemia 6/12/2014 8/1/2017 8/1/2024
glycerol phenylbutyrate Maintenance treatment of patients with deficiencies in enzymes of the urea cycle 4/27/2009 4/28/2017 4/28/2024
ibrutinib Treatment of nodal marginal zone lymphoma 2/5/2015 1/18/2017 1/18/2024
ibrutinib Treatment of chronic Graft versus Host disease. 6/23/2016 8/2/2017 TBD
ibrutinib Treatment of splenic marginal zone lymphoma 2/5/2015 1/18/2017 1/18/2024
ibrutinib Treatment of patients with extranodal marginal zone lymphoma (mucosa associated lymphoid tissue [MALT type] lymphoma) 2/2/2016 1/18/2017 1/18/2024
ipilimumab Treatment of high risk Stage II, Stage III, and Stage IV melanoma 6/3/2004 7/21/2017 7/21/2024
L-glutamine Treatment of sickle cell disease 8/1/2001 7/7/2017 7/7/2024
ledipasvir/sofosbuvir Treatment of chronic hepatitis C virus (HCV) infection in pediatric patients 10/12/2016 4/7/2017 4/7/2024
lenalidomide Treatment of multiple myeloma 9/20/2001 2/22/2017 2/22/2024
methotrexate oral solution Treatment of acute lymphoblastic leukemia in pediatric patients (0 through 16 years of age) 5/28/2015 4/25/2017 4/25/2024
methotrexate oral solution Management of pediatric patients with active polyarticular juvenile idiopathic arthritis (pJIA) who are intolerant of or had an inadequate response to first-line therapy. 8/27/2015 4/25/2017 4/25/2024
midostaurin Treatment of acute myeloid leukemia 7/7/2009 4/28/2017 4/28/2024
midostaurin Treatment of mastocytosis 4/30/2010 4/28/2017 4/28/2024
niraparib Treatment of ovarian cancer 4/30/2010 3/27/2017 3/27/2024
nivolumab Treatment of Hodgkin lymphoma 8/7/2014 4/25/2017 4/25/2024
pembrolizumab Treatment of Hodgkin lymphoma. 12/30/2015 3/14/2017 3/14/2024
regorafenib Treatment of hepatocellular carcinoma 6/4/2015 4/27/2017 4/27/2024
rituximab and recombinant human hyaluronidase Treatment of diffuse large B-cell lymphoma 9/7/2016 6/22/2017 6/22/2024
rituximab and recombinant human hyaluronidase Treatment of chronic lymphocytic leukemia (CLL) 8/22/2016 6/22/2017 6/22/2024
rituximab and recombinant human hyaluronidase Treatment of follicular lymphoma 8/22/2016 6/22/2017 6/22/2024
sofosbuvir Treatment of pediatric chronic hepatitis C virus infection 10/25/2016 4/7/2017 4/7/2024
Sterile talc Treatment of malignant pleural effusion 12/8/1997 5/1/2017 TBD
Sterile talc Treatment of pneumothorax 12/8/1997 5/1/2017 5/1/2024
telotristat etiprate Treatment of carcinoid syndrome in patients with neuroendocrine tumors 3/9/2012 2/28/2017 2/28/2024

Thiotepa

Conditioning treatment prior to hematopoietic stem cell transplantation

4/2/2007

1/26/2017

1/26/2024

triptorelin pamoate

Treatment of central precocious puberty

8/20/2012

6/29/2017

6/29/2024

Tuesday 8 August 2017

Fitbit Loses Wearables Leader Crown


Image result for xiaomi fitness band

Fitbit’s long reign as the top wearables provider in the industry has finally ended with Chinese tech company Xiaomi shipping the most units this quarter. 

According to market analyst firm Strategy Analytics, Xiaomi has now stolen Fitbit’s crown with a market share of just over 17% compared to Fitbit’s 15.7%. It is the first time ever that Xiaomi has led the market.

The firm shipped 3.7 million wearables in Q2 2017, rising 23% since the same time last year. The rise is thought to be attributable to its affordable Mi Band fitness trackers which in China are incredibly popular.

In comparison, Fitbit has been battling with a waning interest in its own fitness tracker range. The firm’s revenue figures signalled a 19% loss compared to Q4 2015.

Shanghai Pharma Partners with DHL to prepare for 'Rapid Global Expansion'


Image result for shanghai pharmaceuticals holding co. ltd

Shanghai Pharmaceuticals, one of China’s largest listed pharma groups, has signed a memorandum of understanding (MOU) with the contract logistics firm DHL Supply Chain, to prepare its logistics infrastructure for what the company calls ‘rapid global expansion.’

Under the MOU, the pharma company – which generated revenues of more than $18 billion last year – will partner with DHL Supply Chain to enhance quality control measures, streamline distribution processes, and strengthen compliance with local and international food and pharmaceutical regulations.

“Our partnership with DHL will help Shanghai Pharma to become one of the world’s foremost pharmaceutical manufacturers – supported by a global distribution network that combines world-class quality control with fast, seamless delivery”- said Cho Man, president and executive director at Shanghai Pharma.

Tuesday 1 August 2017

First HPV (Cervical Cancer) vaccine launched on the Chinese market

First HPV (Cervical Cancer) vaccine launched on the Chinese market. 1st August 2017.
GlaxoSmithKline PLC launched Cervarix, the first HPV vaccine, on the Chinese mainland on Monday. The first imported batch of Cervarix, the cervical cancer vaccine, has passed quality inspections and is heading to health clinics across the Chinese mainland, pharmaceutical company GlaxoSmithKline said on Monday.


The China Food and Drug Administration certified the use of Cervarix on the mainland in July 2016. In May this year, another HPV vaccine, US-based Merck's Gardasil, also gained approval.

Cervical cancer is the third most common cancer among Chinese women aged 15 to 44, with 100,000 new cases diagnosed each year.

The vaccine is registered in 132 countries and regions, and more than 69 million doses have been provided to the global market, according to GSK.




2017 - Record Breaking Year for Orphan Drug Approvals

Food and Drug Administration (FDA) is on track to set a record for orphan drugs approved this year. At last count, 42 orphan drugs have bee...